Loading...
•
Mar 31, 2024
Invivyd Q1 2024 Earnings Report
Invivyd reported financial results for the first quarter of 2024 and provided recent business highlights.
Key Takeaways
Invivyd launched PEMGARDA in the U.S. for COVID-19 pre-exposure prophylaxis and reported interim data from the CANOPY Phase 3 trial. The company ended Q1 with $189.4 million in cash and expects to end 2024 with at least $75 million based on anticipated revenue of $150-$200 million.
Launched PEMGARDA in the U.S. for COVID-19 pre-exposure prophylaxis.
Reported interim exploratory COVID-19 clinical event data from CANOPY Phase 3 clinical trial of VYD222.
Received product-specific reimbursement codes covering PEMGARDA from CMS, covering approximately half of the target population.
Announced plans to pursue rapid immunobridging pathway to potential EUA for COVID-19 treatment.
Forward Guidance
Invivyd expects to end 2024 with at least $75 million in cash and cash equivalents, based on anticipated 2024 net product revenue of $150-$200 million and recent resource realignment.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...